Skip to main content

Table 2 Percentages of TFK-1 in each phase of the cell cycle after 48 hours of exposure to different dosages of rapamycin

From: Tumor growth effects of rapamycin on human biliary tract cancer cells

Group Apoptosisa G0/G1 phase G2 + M phase S phase
  Mean ±SE P b Mean ±SE P b Mean ±SE P b Mean ±SE P b
control 0.15 0.03   37.78 1.67   39.00 1.33   8.9 0.34  
rapa 1 ng/mL 0.11 0.02 0.21 51.75 1.07 <0.001 33.72 0.92 <0.05 5.55 0.43 <0.001
rapa 5 ng/mL 0.09 0.01 <0.05 50.74 1.31 <0.001 35.45 0.69 <0.05 4.10 0.16 <0.001
rapa 10 ng/L 0.08 0.01 <0.05 49.53 1.15 <0.001 35.28 0.66 <0.05 4.38 0.30 <0.001
rapa 20 ng/mL 0.15 0.01 0.92 47.26 1.10 <0.001 35.97 0.87 0.09 5.61 0.13 <0.001
rapa 50 ng/mL 0.19 0.02 0.25 49.86 2.17 <0.001 37.67 1.11 0.46 3.21 0.33 <0.001
  1. Cell cycle analysis of EGI-1 and TFK-1 cell lines 48 hours after treatment with rapamycin at doses of 1, 5, 10 and 20 ng/mL, with 5-bromo-2′-deoxyuridine and 7-aminoactinomycin D staining. aSub G1-region, indicating cells with small DNA fragments, a typical feature of apoptosis; bt-test was performed; while a Levene test was performed in case of unequal variances, P <0.05 was considered significant. rapa: rapamycin; SE: standard error of the mean.